Li Kang Biomedical Co., Ltd. (TPEX:6242)
Taiwan · Delayed Price · Currency is TWD 37.50
-0.20 (-0.53%)
May 20, 2026, 10:52 AM CST
Li Kang Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 575.98 | 589.21 | 565.52 | 629.38 | 684.25 | 386.97 | |
Revenue Growth (YoY) | -0.19% | 4.19% | -10.15% | -8.02% | 76.82% | -15.27% |
Cost of Revenue | 187.79 | 190.96 | 179.42 | 203.23 | 295.68 | 122.29 |
Gross Profit | 388.18 | 398.25 | 386.1 | 426.15 | 388.58 | 264.68 |
Selling, General & Admin | 296.65 | 299.97 | 296.08 | 292.77 | 251.22 | 207.44 |
Operating Expenses | 296.65 | 299.97 | 296.08 | 292.77 | 251.22 | 207.44 |
Operating Income | 91.53 | 98.28 | 90.02 | 133.37 | 137.36 | 57.25 |
Interest Expense | -0.36 | -0.37 | -0.69 | -0.62 | -0.29 | -0.46 |
Interest & Investment Income | 3.96 | 4.67 | 6.37 | 3.29 | 1.6 | 2.21 |
Currency Exchange Gain (Loss) | -0.46 | -0.46 | 0.64 | 0.02 | 0.96 | -0.22 |
Other Non Operating Income (Expenses) | 2.03 | 2.39 | 2.58 | 2.19 | 3.35 | 1.69 |
EBT Excluding Unusual Items | 96.7 | 104.51 | 98.91 | 138.25 | 142.98 | 60.48 |
Gain (Loss) on Sale of Investments | -0.46 | -0.46 | 0.28 | 0.9 | -2.2 | -1.75 |
Other Unusual Items | - | - | - | - | 0.02 | 4.76 |
Pretax Income | 96.24 | 104.05 | 99.19 | 139.14 | 140.8 | 63.48 |
Income Tax Expense | 18.68 | 20.23 | 22.16 | 28.15 | 28.7 | 12.05 |
Net Income | 77.56 | 83.82 | 77.02 | 110.99 | 112.09 | 51.44 |
Net Income to Common | 77.56 | 83.82 | 77.02 | 110.99 | 112.09 | 51.44 |
Net Income Growth | -4.70% | 8.83% | -30.61% | -0.98% | 117.92% | -25.74% |
Shares Outstanding (Basic) | 32 | 32 | 31 | 27 | 27 | 27 |
Shares Outstanding (Diluted) | 32 | 32 | 31 | 27 | 27 | 27 |
Shares Change (YoY) | -0.47% | 2.50% | 15.70% | - | 0.10% | -0.23% |
EPS (Basic) | 2.44 | 2.64 | 2.48 | 4.14 | 4.18 | 1.92 |
EPS (Diluted) | 2.44 | 2.62 | 2.47 | 4.12 | 4.16 | 1.91 |
EPS Growth | -4.52% | 6.07% | -40.05% | -0.96% | 117.46% | -25.49% |
Free Cash Flow | -243.79 | -237.23 | 2.63 | 93.48 | 156.08 | 56.19 |
Free Cash Flow Per Share | -7.67 | -7.42 | 0.08 | 3.47 | 5.79 | 2.09 |
Dividend Per Share | - | 2.000 | 2.000 | 2.500 | 1.739 | 1.242 |
Dividend Growth | - | - | -20.00% | 43.75% | 40.00% | -46.43% |
Gross Margin | 67.40% | 67.59% | 68.27% | 67.71% | 56.79% | 68.40% |
Operating Margin | 15.89% | 16.68% | 15.92% | 21.19% | 20.07% | 14.79% |
Profit Margin | 13.47% | 14.23% | 13.62% | 17.64% | 16.38% | 13.29% |
Free Cash Flow Margin | -42.33% | -40.26% | 0.46% | 14.85% | 22.81% | 14.52% |
EBITDA | 99.15 | 107.08 | 100.38 | 143.05 | 148.35 | 70.14 |
EBITDA Margin | 17.21% | 18.17% | 17.75% | 22.73% | 21.68% | 18.12% |
D&A For EBITDA | 7.61 | 8.79 | 10.36 | 9.68 | 10.99 | 12.89 |
EBIT | 91.53 | 98.28 | 90.02 | 133.37 | 137.36 | 57.25 |
EBIT Margin | 15.89% | 16.68% | 15.92% | 21.19% | 20.07% | 14.79% |
Effective Tax Rate | 19.41% | 19.44% | 22.35% | 20.23% | 20.39% | 18.97% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.